NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Vera Therapeutics, Inc. (VERA) Stock Analysis

Vera Therapeutics, Inc. (VERA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VERA

$35.89

+$0.90 (+2.57%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VERA with… →

VERA Key Statistics

As of Sep 4, 2026
Trading
Open
$34.69
Previous Close
$34.99
Day's Range
34.69–36.41
52-Week Range
22.72–56.05
Volume
1.18M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.95
Valuation
Market Cap
$2.59B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−6.02
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$299.62M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
72.06M
1-Year Return
+63.88%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
2.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VERA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−29.13%
2025+19.74%
2024+174.97%
2023−20.52%
2022−27.58%
2021 (partial year)+132.35%

As of September 4, 2026.

VERA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$299.62M—
2024$0.00−$152.15M—
2023$0.00−$95.99M—
2022$0.00−$89.06M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$315.47M−$299.62M—
2024$0.00—−$167.17M−$152.15M—
2023$0.00—−$102.01M−$95.99M—
2022$0.00—−$90.90M−$89.06M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VERA Valuation vs Biotechnology Median

Median of 656 stocks
MetricVERABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Vera Therapeutics, Inc. (VERA) carries a market capitalisation of $2.59B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 361 employees.

The most recent close on file for VERA is $35.89, dated September 4, 2026. That is +$0.90 (+2.57%) against the previous close. The 52-week range on file runs from $22.72 to $56.05. The latest close sits 57.97% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $299.62M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −6.02.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +63.88%. Measured over 5 years, that is +6.82% a year compounded. Beta against the wider market is reported at 0.95. Annualized volatility over the trailing 5 years is 87.91%.

Growth & Income

No dividend is on file for VERA.

The strongest complete calendar year on file is 2024 at +174.97%; the weakest is 2022 at −27.58%. Of the 4 complete calendar years on file, 2 finished higher. So far in 2026 the price is −29.13%.

Peer Comparison

Vera Therapeutics, Inc. (VERA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vera Therapeutics, Inc. VERA $2.59B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Vera Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Visit website →